Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

• Status: Withdrawn
• Trial end date: 2025-09-01

Summary

This clinical trial is an open-label, single arm study evaluating the safest dose of lorlatinib in combination with standard of care chemotherapy in participants with metastatic anaplastic lymphoma kinase positive (ALK+) NSCLC who progressed on prior therapy of lorlatinib alone. The main goals of this study are to:

• Evaluate the safety and tolerability of lorlatinib in combination with standard of care chemotherapy.

• Evaluate how well the combination of lorlatinib and standard of care chemotherapy works to treat metastatic anaplastic lymphoma kinase positive (ALK+) NSCLC.

• Evaluate the pharmacokinetics (PK) of lorlatinib when given in combination with standard of care chemotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Pfizer
• Treatments: Carboplatin; Cisplatin; Pemetrexed